.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR27_LamivudineTenofovirDisop.LamivudineTenofovirDisop .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR27_LamivudineTenofovirDisop.LamivudineTenofovirDisop| name: | LamivudineTenofovirDisoproxilAndDolutegravir | |
| ATC code: | J05AR27 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 90 | L |
| clearance: | 11 | L/h |
| other parameters in model implementation | ||
Lamivudine, tenofovir disoproxil, and dolutegravir is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection in adults and adolescents. Each drug targets HIV at a different replication stage: lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor (NtRTI), and dolutegravir is an integrase strand transfer inhibitor (INSTI). The drug is widely approved and used globally as part of first-line HIV therapy.
Estimated pharmacokinetic parameters for a typical adult population (healthy HIV-negative volunteers or adults with HIV infection) for the fixed-dose oral combination tablet once daily.